Markus Boehm

Title: Innovations of Markus Boehm in Pharmaceutical Combinations

Introduction

Markus Boehm is a notable inventor based in Rheinfelden, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative drug combinations. His work focuses on addressing proliferative diseases through targeted therapies.

Latest Patents

Markus Boehm holds a patent for "Synergistic combinations of PI3K- and MEK-inhibitors." This pharmaceutical combination comprises (a) the phosphatidylinositol 3-kinase (PI3K) inhibitor compound (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]thiazol-2-yl}-amide) or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt. The patent also discusses the uses of such combinations in the treatment of proliferative diseases and methods for administering a therapeutically effective amount of the combination.

Career Highlights

Markus Boehm is currently associated with Novartis AG, a leading global healthcare company. His role involves research and development in the pharmaceutical sector, where he applies his expertise to create effective treatment options for various diseases.

Collaborations

Markus has collaborated with notable colleagues such as Christine Fritsch and Xizhong Huang. Their combined efforts contribute to advancing research in the pharmaceutical field.

Conclusion

Markus Boehm's innovative work in pharmaceutical combinations showcases his commitment to improving treatment options for proliferative diseases. His contributions are significant in the ongoing quest for effective therapies in the medical field.